Lenalidomide Sandoz

Lenalidomide, the active ingredient in Lenalidomide Sandoz, is an immunomodulatory agent (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Lenalidomide Sandoz is used in hematologic malignancies that respond to immunomodulatory therapy. - Multiple Myeloma: improves progression‑free survival and overall response in relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and prolongs survival. - Mantle Cell Lymphoma: enhances response rates when combined with standard chemotherapy regimens.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Rash: skin irritation or erythema. - Nausea: upset stomach often alleviated with food. - Cytopenias: reduced blood cell counts, especially neutrophils.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Secondary malignancies: rare development of new cancers.

Before initiating therapy, clinicians should assess patient risk factors and monitor laboratory parameters. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thromboembolism: evaluate need for prophylactic anticoagulation. - Renal function: adjust monitoring in patients with impaired kidney function. - Hepatic impairment: consider liver function tests before and during treatment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - Immunosuppressants: heightened infection risk. - P-glycoprotein inhibitors: may increase plasma concentrations. - NSAIDs: additive risk of renal impairment. - Vaccines: live vaccines should be avoided during therapy.